 |
市场调查报告书
商品编码
1705673
白细胞介素抑制剂市场：按类型、按给药途径、按应用、按分销管道、按地区Interleukin Inhibitors Market, By Type, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
预计 2025 年全球白细胞介素抑制剂市场规模为 367.8 亿美元，到 2032 年将达到 855.1 亿美元，2025 年至 2032 年的复合年增长率为 12.8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 367.8亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年复合年增长率： | 12.80% | 2032年价值预测 | 855.1亿美元 |
白细胞介素抑制剂是阻断或减弱白细胞白细胞介素细胞因子活性的生技药品，白细胞介细胞激素因子在引发发炎方面发挥重要作用。这些蛋白质作为重要的讯号分子，引导白血球迁移到受伤或感染的部位。然而，过度或长期的发炎会引起问题。白细胞介素抑制剂针对特定的白细胞介素，有助于控制由不适当或过度的免疫反应引起的疾病。关键的白细胞介素标靶包括 IL-17、IL-23 和 IL-1B，它们与自体免疫疾病有关。随着新型生技药品被核准用于治疗各种发炎和免疫介导疾病，全球白细胞介素抑制剂市场正在稳步增长。
市场动态：
全球白细胞介素抑制剂市场受到全球免疫介导疾病日益流行的推动以及医疗保健支出的增加。根据世界卫生组织估计，到2025年11月，全球约有2-3%的人口将受到自体免疫疾病的影响，其中许多病例未被诊断或治疗。新型白细胞介素抑制剂核准用于治疗干癣性关节炎、僵直性脊椎炎和溃疡性大肠炎等医疗需求未满足的疾病，这也推动了市场的成长。然而，生技药品的高成本对价格敏感的新兴市场的市场扩张构成了重大挑战。此外，重磅药物的专利悬崖进一步加剧了竞争。然而，正在进行的研究和开发具有改进的安全性和新的治疗适应症的白细胞介素抑制剂为市场参与者提供了一个有吸引力的机会。
本研究的主要特点
本报告对全球白细胞介素抑制剂市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
它还揭示了不同领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
全球白细胞介素抑制剂市场的主要企业根据公司亮点、产品系列、关键亮点、性能和策略等参数进行分析。
研究涉及的主要企业包括 AbbVie Inc.、强生公司、安进公司、诺华公司、赛诺菲公司、葛兰素史克公司、礼来公司、再生元製药公司、默克公司、工业、Biogen Inc.、UCB SA、安斯泰来製药公司、拜耳公司和山德士国际有限公司。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员将透过分析全球白细胞介素抑制剂市场所使用的各种策略矩阵来更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要进展
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 产业趋势
4. 2020 年至 2032 年全球白细胞介素抑制剂市场（按类型）
- IL-1抑制剂
- IL-5抑制剂
- IL-6抑制剂
- IL-17抑制剂
- IL-23抑制剂
- 其他类型
5. 全球白细胞介素抑制剂市场（依给药途径），2020 年至 2032 年
- 口服
- 皮下（SC）
- 静脉注射（IV）
- 其他的
6. 全球白细胞介素抑制剂市场（依应用划分），2020 年至 2032 年
- 类风湿性关节炎
- 干癣性关节炎
- 干癣
- 发炎性肠道疾病（IBD）
- 气喘
- 多发性硬化症
- 溃疡性大肠炎
- 克隆氏症
- 其他用途
7. 全球白细胞介素抑制剂市场（依分销管道划分），2020-2032 年
- 医院药房
- 零售药局
- 网路药局
8. 全球白细胞介素抑制剂市场（按地区），2020-2032
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第九章竞争格局
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi SA
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB SA
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
第 10 章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第 11 章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is expected to reach USD 85.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 36.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.80% | 2032 Value Projection: | USD 85.51 Bn |
Interleukin inhibitors are biologics that block or dampen the activity of interleukin cytokines that play important roles in triggering inflammation. These proteins act as signaling molecules that are critical in directing the movement of white blood cells to sites of injury or infection. However, excess or prolonged inflammation can cause issues. Interleukin inhibitors help control conditions driven by inappropriate or excessive immune responses by targeting specific interleukins. Some key interleukin targets include IL-17, IL-23, and IL-1B that are implicated in autoimmune diseases. The global interleukin inhibitors market has been growing steadily as new biologics gain regulatory approvals for treating various inflammatory and immune-mediated disorders.
Market Dynamics:
The global interleukin inhibitors market is driven by the increasing prevalence of immune-mediated conditions worldwide coupled with rising healthcare expenditures. In November 2025, according to the WHO estimates, around 2-3% of the global population suffers from autoimmune diseases with many cases remaining undiagnosed or untreated. Approvals of novel interleukin inhibitors for treating diseases with high unmet needs such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis are also boosting the market growth. However, high costs of biologics pose a major challenge for market expansion in price-sensitive developing regions. Moreover, patent cliffs of blockbuster drugs further intensify competition. Nevertheless, ongoing R&D for developing interleukin inhibitors with improved safety profiles and new therapeutic indications provide attractive opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global interleukin inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global interleukin inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global interleukin inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interleukin inhibitors market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2020 - 2032)
- IL-1 inhibitors
- IL-5 inhibitors
- IL-6 inhibitors
- IL-17 inhibitors
- IL-23 inhibitors
- Other types
- By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
- Others
- By Application Insights (Revenue, USD Bn, 2020 - 2032)
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Asthma
- Multiple Sclerosis
- Ulcerative colitis
- Crohn's disease
- Other applications
- By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Interleukin Inhibitors Market, By Type
- Global Interleukin Inhibitors Market, By Route of Administration
- Global Interleukin Inhibitors Market, By Application
- Global Interleukin Inhibitors Market, By Distribution Channel
- Global Interleukin Inhibitors Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Interleukin Inhibitors Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- IL-1 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- IL-5 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- IL-6 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- IL-17 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- IL-23 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Interleukin Inhibitors Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Interleukin Inhibitors Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Rheumatoid arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Psoriatic arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inflammatory bowel disease (IBD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ulcerative colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Interleukin Inhibitors Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Interleukin Inhibitors Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
